MedTrace Logo

Effect of a Probiotic Formula on Reducing SIBO in IBS Patients

NCT04316806 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2022-11-08

No results posted yet for this study

Summary

This randomized study evaluates the effectiveness of the a probiotic formula, compared with the antibiotic rifaximin, in the treatment of Small Intestinal Bacterial Overgrowth (SIBO) in Irritable Bowel Syndrome (IBS) patients.

Conditions

  • Irritable Bowel Syndrome
  • Small Intestinal Bacterial Overgrowth

Interventions

DIETARY_SUPPLEMENT

Probiotic

Probiotic (dietary supplement) administrated once daily (u.i.d) for 8 weeks (3 billion cfus per day)

DRUG

Rifaximin

Antibiotic rifaximin consisting 400 mg capsules administrated twice daily (b.i.d) for 1week.

Sponsors & Collaborators

  • AB Biotics, SA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-20
Primary Completion
2022-09-01
Completion
2022-09-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04316806 on ClinicalTrials.gov